Pyridin-3-essigsaeure-N-ethylamid | 743390-05-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Pyridin-3-essigsaeure-N-ethylamid
• 英文别名: N-ethyl-2-pyridin-3-yl-acetamide；N-ethyl-2-pyridin-3-ylacetamide
• CAS: 743390-05-8
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: ZAIQURYCORZRBP-UHFFFAOYSA-N

物化性质

• 沸点：
  377.7±25.0 °C(Predicted)
• 密度：
  1.063±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Pyridin-3-essigsaeure-N-ethylamid 在 硼烷 作用下， 以 四氢呋喃 为溶剂， 生成 2-(2-Pyridyl-(3))-diethylamin
  参考文献：
  名称：

  3-(2-Aminoethyl)pyridine analogs as α4β2 nicotinic cholinergic receptor ligands

  摘要：

  An examination of several 3-(2-aminoethyl)pyridine analogs suggests that they likely orient at x4 beta 2 nicotinic cholinergic receptors in a different fashion than their correspondingly substituted nicotine analogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.053
• 作为产物：
  描述：

  3-吡啶乙酸 、 乙胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 Pyridin-3-essigsaeure-N-ethylamid
  参考文献：
  名称：

  3-(2-Aminoethyl)pyridine analogs as α4β2 nicotinic cholinergic receptor ligands

  摘要：

  An examination of several 3-(2-aminoethyl)pyridine analogs suggests that they likely orient at x4 beta 2 nicotinic cholinergic receptors in a different fashion than their correspondingly substituted nicotine analogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.053

文献信息

• Heterobicyclic thiophene compounds and methods of use
  申请人：Blake F. James

  公开号：US20070197537A1

  公开（公告）日：2007-08-23

  Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物及其药用盐可用于抑制受体酪氨酸激酶，并用于治疗由此介导的疾病。公开了使用公式I的化合物及其药用盐的方法，用于体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理情况。
• Pharmaceutically Active Diazepanes
  申请人：Oberhauser Berndt

  公开号：US20080300237A1

  公开（公告）日：2008-12-04

  Leukocyte Function-Associated Antigen One (LFA-1) is a cell adhesion molecule selectively expressed on leukocytes, and plays a major role in the activation and trafficking of T lymphocytes in the tissue at sites of inflammation. In the last decade a large body of preclinical data has accumulated to establish the importance of LFA-1 as a biological target, 10 particularly in chronic, T-cell driven inflammatory conditions. The present invention provides pharmaceutically active 1,4-diazepan-2-ones of formula I useful for the treatment of conditions related to LFA-1 activity.

  白细胞功能相关抗原一（LFA-1）是一种细胞黏附分子，选择性地表达在白细胞上，对于在炎症部位的组织中T淋巴细胞的激活和转移起着重要作用。在过去的十年中，大量的临床前数据已经积累，以确定LFA-1作为生物学靶点的重要性，特别是在慢性的、T细胞驱动的炎症情况下。本发明提供了公式I的药物活性1,4-二氮杂环己烷-2-酮，用于治疗与LFA-1活性相关的疾病。
• PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS
  申请人：DeMeese Jason

  公开号：US20110130406A1

  公开（公告）日：2011-06-02

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化学式Ia和Ib的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物、代谢产物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。本文揭示了使用化学式Ia和Ib的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物和药学上可接受的盐的方法，用于哺乳动物细胞中的体外、体内诊断、预防或治疗这种疾病或相关病理条件。
• PHARMACEUTICALLY ACTIVE DIAZEPANES
  申请人：Novartis AG

  公开号：EP1874739B1

  公开（公告）日：2010-05-26
• US8003660B2
  申请人：——

  公开号：US8003660B2

  公开（公告）日：2011-08-23